Radius Research
meticulous due diligence. Under the astute leadership of Founder Martin Gagle, the firm has embarked on a mission to demystify the investment landscape, one insightful conversation at a time. Martin hosts a weekly video series, engaging in enlightening discussions with C-suite executives from every corner of the globe, thereby bridging the informational chasm that often exists between companies and potential investors. This initiative not only shines a light on the visions and ventures of seasoned CEOs but also unveils emerging companies poised to make a significant impact in the industry. Radius Research transcends the conventional advisory role by facilitating a platform where ideas exchange hands and trust is the currency. The firm’s offerings are not just robust but come with a stamp of Institutional Quality, ensuring clients are well-equipped with the acumen necessary to navigate the complex financial waters. Through its unwavering commitment to transparency and quality, Radius Research Investments is not just a service provider, but a companion in the investment journey.
Revolve Renewable Power (REVV) 608% Revenue Growth and $2.6 million earnings - CEO Steve Dalton
Star Royalties (STRR) CIO Kevin MacLean: Proposed Acquisition of Sabre Gold by Minera Alamos
NeuPath Health (NPTH) Joe Walewicz CEO of Canada's largest chronic pain management services provider
Rakovina Therapeutics (RKV) Exec Chairman Jeffrey Bacha discusses AI generated drug candidates
Wedgemount Resources (WDGY) CEO Mark Vanry: Innovative Low Cap-Ex & Lo-Risk Growth Model
Satellos Bioscience (MSCL) CEO Frank Gleeson: Phase 1 & 2 Milestones for 2024-2025 targeting DMD
MustGrow Biologics (MGRO) CEO Corey Giasson give update on commercialization & global partnerships
Rakovina Therapeutics (RKV) Exec Chair Jeffery Bacha: A.I. powered drug discovery with out-licensing
Turnium Tech (TTGI) CEO Doug Childress & Chairman Ralph Garcea acquisition synergies and growth.